Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line Osimertinib in the Real World: an Inter-regional Prospective Study: FLOWER

NCT04965701 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT04965701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04965701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line Osimertinib in the Real World: an Inter-regional Prospective Study: FLOWER
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Observational
Overall status
Completed
Start date
June 1, 2018
Completion date
May 31, 2023
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egf-r positive non-small cell lung cancer